News

New investors for Genmedica
Enlarge image

BusinessSpainUK

New investors for Genmedica

19.10.2012 - Spanish Genmedica Therapeutics S.L. has raised €12m in a series B financing round led by the British investor Asclepios Bioresearch.

Genmedica develops dual action, small molecules which act against both oxidative stress and inflammation (OSIF), two processes that are emerging as critical in the pathogenesis of a wide range of diseases. It’s lead compound GMC-252 has shown in multiple type 2 diabetes animal models to act as a potent anti-diabetic, lowering glucose and lipids. „The deal with Asclepios allows us to quickly advance our clinical plans with an experienced partner and start dosing patients this year. This will allow us to generate phase 1 safety data in 2013 and preliminary efficacy data in early 2014“, stated Alec Mian, CEO of Genmedica.

In 2011, the Barcelona-based start upo raised €3m in a series A round from local investors Caxia Capital, BcnEmpren, Unifondo-Uninvest and Venture Cap.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-04/new-investors-for-genmedica.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC (D)3.54 EUR10.62%
  • DEINOVE (F)7.10 EUR7.25%
  • NANOBIOTIX (F)18.43 EUR5.62%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • OREXO (S)45.30 SEK-8.67%
  • TIGENIX (B)1.12 EUR-7.44%

TOP

  • KARO BIO (S)40.60 SEK2502.6%
  • BIOTECH PHARMACON (N)17.40 NOK84.5%
  • TRANSGENE (F)4.86 EUR73.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • BIONOR PHARMA (N)1.17 NOK-44.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)12.85 SEK-43.4%

TOP

  • KARO BIO (S)40.60 SEK4566.7%
  • ADOCIA (F)85.64 EUR389.7%
  • VERONA PHARMA (UK)4.95 GBP312.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)12.85 SEK-80.2%
  • BIOTEST (D)20.00 EUR-77.0%

No liability assumed, Date: 02.09.2015